Aug 10, 2026 07:30AM
Aug 10, 2026 07:30AM
Aug 3, 2026 04:05PM
Jun 16, 2026 04:06PM
Jun 16, 2026 04:05PM
Jun 12, 2026 08:01AM
Jun 12, 2026 08:00AM Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
Jun 4, 2026 07:45AM
Jun 4, 2026 07:45AM
May 27, 2026 05:00PM
May 27, 2026 05:00PM
May 5, 2026 04:05PM
Apr 27, 2026 07:45AM
Apr 27, 2026 07:45AM Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Me
Apr 21, 2026 04:05PM
Apr 9, 2026 07:45AM
Mar 24, 2026 01:49PM
Mar 18, 2026 07:44AM
Feb 24, 2026 04:05PM
Jan 12, 2026 07:06AM
Jan 12, 2026 07:05AM Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer
Jan 6, 2026 01:33PM
Jan 6, 2026 01:32PM
Dec 5, 2025 09:01AM
Dec 5, 2025 09:00AM
Dec 2, 2025 04:05PM
Dec 2, 2025 04:05PM
Nov 18, 2025 04:59AM Jazz Pharmaceuticals (JAZZ) PT Raised to $247 at BofA Securities
Nov 17, 2025 06:00AM
Nov 17, 2025 06:00AM
Nov 11, 2025 07:45AM
Nov 11, 2025 07:45AM
Nov 5, 2025 04:05PM
Oct 3, 2025 08:05AM
Oct 2, 2025 06:38PM FDA approves Jazz Pharmaceuticals' Zepzelca combo for lung cancer treatment
Oct 2, 2025 06:37PM
Oct 2, 2025 03:33PM
Sep 22, 2025 07:45AM
Sep 22, 2025 07:45AM
Sep 11, 2025 08:18AM
Sep 9, 2025 07:45AM
Sep 9, 2025 07:45AM Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
Aug 20, 2025 04:15PM
Aug 6, 2025 03:08PM
Aug 6, 2025 03:07PM
Aug 6, 2025 02:24PM
Aug 5, 2025 04:05PM
Jul 1, 2025 08:32AM
Jul 1, 2025 08:31AM Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
Jun 11, 2025 07:15AM

328,333 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All